Analyst Update: Alcatel Lucent, AT&T, GlaxoSmithKline

Analysts adjusted their ratings on ALU, T, and GSK

Oct 23, 2014 at 11:40 AM
facebook X logo linkedin


Analysts are weighing in today on networking firm Alcatel Lucent SA (ADR) (NYSE:ALU), telecom issue AT&T Inc. (NYSE:T), and pharmaceutical power GlaxoSmithKline plc (ADR) (NYSE:GSK). Here's a quick look at today's brokerage notes on ALU, T, and GSK.

  • ALU is up 4.8% to trade at $2.61, after being upgraded to "hold" from "underperform" at Jefferies. Nevertheless, the shares remain nearly 41% lower on a year-to-date basis, and are facing overhead resistance from their descending 20-day moving average, located at $2.69. Additionally, the equity recently hit a fresh 12-month low. In spite of these unimpressive long-term technicals, Alcatel Lucent SA's (ADR) 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) checks in at 27.53. Relative to the past year's worth of readings, the current ratio ranks in the 70th annual percentile, signaling an unusually strong preference for long ALU calls over puts. On the fundamental front, the company will report third-quarter earnings before the open next Thursday, Oct. 30.

  • T has shed 2.7% to churn near $33.56, after a disappointing third-quarter earnings report prompted no fewer than five brokerage firms to lower their price targets on the security. Similarly, Hilliard Lyons downgraded the stock to "neutral" from "long-term buy." On the other side of the fence, Cowen raised its price target on AT&T Inc. to $39 from $38, to go along with its "market perform" opinion. On the charts, the equity has lost 4.5% in 2014. Elsewhere, options traders have been betting more bearishly than usual on T, per its 10-day ISE/CBOE/PHLX put/call volume ratio of 1.35, which sits higher than more than three-quarters of all other readings from the last year.

  • GSK has tacked on 2.5% to trade at $45.54, following news that the firm may float its HIV unit, Viiv Healthcare. Also helping the shares was an upgrade to "overweight" from "equal weight," and price-target hike to 1,600 pounds from 1,485 pounds, at Barclays -- although Bryan Garnier, Deutsche Bank, and Leerink all slashed their respective price targets. Overall, it's not been a good year for GlaxoSmithKline plc (ADR), which is down nearly 15% in 2014. Not surprisingly, Wall Street is skeptically arrayed toward the stock, with seven "hold" and "strong sell" ratings outweighing just one "strong buy."
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI